TRIO Pharmaceuticals raised $3.1 million in a pre-Series A financing round led by Friedman Bioventure Fund to advance cancer therapeutics.

Dec 03, 2024•about 1 year ago

Amount Raised

$3.1 Million

Round Type

series a

San DiegoBiotechnology

Investors

Life Science AngelsNu Fund Venture GroupMultiple Myeloma Research FoundationFriedman Bioventure Fund

Description

TRIO Pharmaceuticals has successfully completed a $3.1 million pre-Series A financing round, focused on developing bispecific antibodies for cancer treatment. The funding was led by Friedman Bioventure Fund, with additional support from the Multiple Myeloma Research Foundation and other investors.

Company Information

Company

Trio Pharmaceuticals

Location

11956 Bernardo Plaza Drive, Suite 160

San Diego, California, United States

About

TRIO Pharmaceuticals, Inc. is a cancer immunotherapeutics company pioneering bispecific antibodies for the treatment of cancer with unprecedented potency and selectivity. TRIO’s innovative antibody drugs directly stop tumor growth without affecting normal cells and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. TRIO is developing a proprietary platform of dual-action tumor immunity-enhancing drugs aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells. TRIO has an experienced team that has developed first-in-class FDA-approved drugs.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns